Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Non Operating Income (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Non Operating Income for 16 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 122.09% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $88.0 million through Dec 2025, up 83.3% year-over-year, with the annual reading at -$89000.0 for FY2025, 99.56% up from the prior year.
  • Non Operating Income hit $1.5 million in Q4 2025 for Ligand Pharmaceuticals, down from $86.2 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $110.5 million in Q1 2024 to a low of -$46.3 million in Q2 2024.
  • Historically, Non Operating Income has averaged $4.9 million across 5 years, with a median of -$224000.0 in 2021.
  • Biggest YoY gain for Non Operating Income was 515500.0% in 2023; the steepest drop was 117192.31% in 2023.
  • Year by year, Non Operating Income stood at -$19.8 million in 2021, then skyrocketed by 96.0% to -$793000.0 in 2022, then skyrocketed by 461.66% to $2.9 million in 2023, then tumbled by 334.03% to -$6.7 million in 2024, then surged by 122.09% to $1.5 million in 2025.
  • Business Quant data shows Non Operating Income for LGNDZ at $1.5 million in Q4 2025, $86.2 million in Q3 2025, and $2.8 million in Q2 2025.